Dr Reddy's Shares Up Nearly 5%, Rising For Sixth Session As Optimism Lifts Sentiment

Mumbai, June 29: Dr Reddy’s Laboratories share price rose as much as five per cent on Monday, extending gains for a sixth session and highlighting the company’s improving earnings outlook and strategic transformation. 

The stock has outperformed the broader market over the past week, reflecting growing optimism over its medium-term growth prospects. As of writing it was up 2.5% at Rs 1,384.  

The stock advanced after the US Food and Drug Administration (USFDA) concluded an inspection of Dr Reddy’s biologics manufacturing facility in Bachupally, Hyderabad, issuing seven observations. According to brokerage Nomura, cited by Informist, most of the observations pertained to the facility’s newly commissioned block, which has been built to manufacture the biosimilar Abatacept, while the older block continues to produce Rituximab. The brokerage said the company remains on track to launch biosimilar Abatacept in the fourth quarter of FY27. 

Nomura described the outcome of the inspection as “modestly encouraging”, noting that the company’s clarification that the bulk of the observations relate to the new block eased some regulatory concerns. However, it cautioned that obtaining USFDA approval for commercial manufacturing at the new facility remains a key milestone. The brokerage added that product-specific regulatory risks appear limited, as the observations were largely related to the manufacturing site rather than the biosimilar product itself. 

Brokerages turn constructive 

The recent rally has been supported by favourable commentary from several brokerages, which have highlighted Dr Reddy’s evolving business mix. 

Stock has flown 7% over a week as markets and brokers cheer prospects. Source: NSE 

Analysts see the company benefiting from a gradual shift towards branded generics and consumer healthcare products, businesses that typically offer more stable margins than the highly competitive U.S. generics market. Brokerages also expect recent acquisitions and new product launches to support revenue growth over the coming quarters. 

Analysts believe the company’s diversified geographical presence, coupled with a robust product pipeline, positions it well to navigate pricing pressure in the global generics market while delivering sustainable earnings growth. 

Focus shifts beyond U.S. generics 

Investors have also welcomed Dr Reddy’s efforts to reduce its dependence on the U.S. generics business, which has remained under pressure due to intense competition and pricing erosion. 

The company has increasingly focused on expanding its presence in India, emerging markets and consumer healthcare while selectively pursuing high-value opportunities in regulated markets. This strategy is expected to provide greater earnings visibility and reduce volatility associated with the U.S. business. 

Brokerages noted that improving execution in domestic formulations, coupled with contributions from specialty products and over-the-counter brands, could help offset challenges in export markets. 

Outlook remains positive 

Analysts expect Dr Reddy’s to remain in focus over the coming weeks as investors monitor quarterly earnings, regulatory developments and progress on new product launches. 

While pricing pressure in the U.S. generics market remains a key risk, brokerages believe the company’s improving business mix, healthy balance sheet and consistent execution provide a strong foundation for long-term growth. 

With sentiment improving and institutional buying gathering pace, investors will be watching whether Dr Reddy’s can sustain its recent momentum and continue outperforming both the broader pharmaceutical sector and the benchmark indices. 

Source: 

• https://www.nseindia.com/get-quote/equity/DRREDDY/Dr.-Reddy’s-Laboratories-Limited